Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials
Sign Up to like & getrecommendations! Published in 2022 at "ESMO Open"
DOI: 10.1016/j.esmoop.2022.100396
Abstract: Background Immune checkpoint inhibitors (ICIs) and genomic biomarker-driven targeted therapies have revolutionized the modern oncologic treatment arsenal. The next step has been to combine targeted agents and ICIs. In doing so, some combination regimens may… read more here.
Keywords: differential expression; expression immunoregulatory; expression; presence ... See more keywords